Drug Approval | November 09, 2023
Lupin launches Rocuronium Bromide injection in US
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Lupin enters into BTA with Lupin Manufacturing Solutions
Balaxi Healthcare Ecuador S.A.S. has become a Wholly Owned Subsidiary of the company
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Mankind Pharma commences the commercial operations newly set-up plant in Udaipur
Norepinephrine Bitartrate Injection is used for restoration of blood pressure in adult patients
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
The inspection was a cGMP Inspection and had ended with NIL observations
Subscribe To Our Newsletter & Stay Updated
